The EPS projection of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for quarter ended 2016-09-30 is $-1.59. Last week, the EPS estimate was $-1.59 against target of $-1.59, a month earlier.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted that 18 days earlier, the share price was revised 1 times on upside. In addition, negative revisions were 1. While 2-months ago, the estimate of EPS was $-1.59 versus forecast of $-1.59 a quarter earlier, recording a deviation of 0%.
Negative EPS revisions in last week were 0 and positive EPS revisions were 0. Positive revisions In last one-month and 2-month were 0 and 1, respectively. In last 120 and 90 days, they were 1, and 1, correspondingly.
The EPS downgrade for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the preceding 30 and 120 were 0 and 4, correspondingly. In last 60 and 90 days were 0, and 4, in that order.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EPS target was $-1.59 for the quarter closed 1. It was based on 9 calls. As on 2016-05-09 the EPS was $-1.35. The change was $-0.06, posting a deviation of -4.65%. The price projections indicated a standard deviation of 0.15.
An earnings surprise happens when a firm’s reported annual or quarterly profits are below or above analysts’ expectations. These professionals, who work for a number of reporting agencies and financial firms, base their expectations on different sources like previous quarterly or yearly results, current market conditions, and also the company’s own financial earnings’ “guidance” or predictions.
Quarterly Sales Estimates
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) sales prediction for the fiscal 2016 stands at $2.505 and the median estimate is at $2.505. Almost 2 analysts gave sales target. As per them, the highest sales estimate is $4.49 while the lowest target is $0.52 showing standard deviation of 2.807%.
As many as 2 experts released upped sales revision while 2 reduced sales estimates, which means the deviation is 0%.
Last month, 2 experts released sales revision. Also, 2 groups lowered the sales targets, which leads top a deviation of 0%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast, giving a deviation of 0%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...